Friday, December 05, 2014 3:39:53 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108805585
Yeah, these are run-of-the-mill results for a monotherapy trial. But the business model of ONCS is no longer that of a monotherapy company. I believe we'll see that come out more during the conference call on Tuesday.
Oh, and here is something to brighten your day:
http://www.wsj.com/video/immunotherapy-how-a-former-cop-beat-cancer/11325F03-9EA6-4B83-A2F9-619856C64ADD.html?mod=trending_now_video_3
Do you know what drug is being used?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM